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Abstract
Background: Ciclesonide is a new inhaled corticosteroids licensed for the prophylactic treatment of
persistent asthma in adults. Currently beclomethasone dipropionate, budesonide and fluticasone
propionate are the most commonly prescribed inhaled corticosteroids for the treatment of asthma but
there has been no systematic review comparing the effectiveness and safety ciclesonide to these agents.
We therefore aimed to systematically review published randomised controlled trials of the effectiveness
and safety of ciclesonide compared to alternative inhaled corticosteroids in people with asthma.
Methods:  We performed literature searches on MEDLINE, EMBASE, PUBMED, the COCHRANE
LIBRARY and various Internet evidence sources for randomised controlled trials or systematic reviews
comparing ciclesonide to beclomethasone or budesonide or fluticasone in adult humans with persistent
asthma. Data was extracted by one reviewer.
Results: Five studies met the inclusion criteria. Methodological quality was variable. There were no trials
comparing ciclesonide to beclomethasone. There was no significant difference between ciclesonide and
budesonide or fluticasone on the following outcomes: lung function, symptoms, quality of life, airway
responsiveness to a provoking agent or inflammatory markers. However, the trials were very small in size,
increasing the possibility of a type II error. One trial demonstrated that the combined deposition of
ciclesonide (and its active metabolite) in the oropharynx was 47% of that of budesonide while another trial
demonstrated that the combined deposition of ciclesonide (and its active metabolite) in the oropharynx
was 53% of that of fluticasone. One trial demonstrated less suppression of cortisol in overnight urine
collection after ciclesonide compared to fluticasone (geometric mean fold difference = 1.5, P < 0.05) but
no significant difference in plasma cortisol response.
Conclusion: There is very little evidence comparing CIC to other ICS, restricted to very small, phase II
studies of low power. These demonstrate CIC has similar effectiveness and efficacy to FP and BUD (though
equivalence is not certain) and findings regarding oral deposition and HPA suppression are inconclusive.
There is no direct comparative evidence that CIC causes fewer side effects since none of the studies
reported patient-based outcomes.
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Background
Inhaled corticosteroids (ICS) have a central role in the
treatment of asthma. They are the most effective prophy-
lactic agents available, particularly in patients with mild
to moderate asthma and persistent symptoms[1] and are
recommended for most adult patients with chronic
asthma whose symptoms are not controlled by inhaled
short acting β 2 agonists [2-4]. Regular treatment with cor-
ticosteroids reduces exacerbations, improves control of
symptoms and lung function, while reducing hospital
admissions and deaths from asthma[1,5]. However, pro-
longed use in persistent asthma and increased doses in
severe cases may result in suppression of the hypotha-
lamic pituitary adrenal (HPA) system with concern that
this might cause growth impairment in children (includ-
ing premature closure of the epiphyses of long bones),
disturbed glucose tolerance, decreased mineralisation of
bone (increasing the risk of fractures), ocular problems
such as glaucoma and cataracts as well as thinning of the
skin [6-8]. Local adverse affects, even at low doses may
include dysphonia, pharyngitis and oral candidiasis[2,9].
The mainstay of ICS treatment has been with three agents:
beclomethasone dipropionate (BDP), budesonide (BUD)
and, more recently, fluticasone propionate (FP). All these
agents are similar chemically and structurally but have dif-
ferent pharmacodynamic properties resulting in different
clinical effects[10]. A Cochrane review of 48 studies com-
paring the three agents concluded that FP given at half the
daily dose of BDP or BUD leads to small improvement in
measures of airway calibre (peak expiratory flow (PEF)
and forced expiratory volume in one second (FEV1) while
at the same daily dose FP appears to have a higher risk of
side effects than BDP or BUD[10].
Ciclesonide (CIC) is a new ICS, manufactured by Altana
Pharma Ltd. CIC is licensed only for the treatment of per-
sistent asthma in adults (18 years older) and is delivered
via a hydrofluoroalkane metered-dose inhaler (HFA MDI)
in 40, 80 and 160 mcg formulations. The recommended
starting dose is 160 mcg given in the evening, with reduc-
tion to 80 mcg for maintenance[11]. These doses are "ex-
actuator", i.e. the dose expelled, as opposed to "ex-valve"
i.e. the actual dose contained in the inhaler (for consist-
ency, throughout this review ex-valve doses are used for all
inhalers).
Ciclesonide has little anti-inflammatory activity itself and
requires cleavage by endogenous carboxyl esterases in the
lung, which creates the active metabolite desisobutryl-
ciclesonide (des-CIC)[12]. This targets activity at the
desired location. Des-Ciclesonide undergoes rapid
hepatic metabolism into inactive metabolites on leaving
the lung[13]. These factors, together with the fact that
ciclesonide has very low oral bioavailability due to almost
complete first pass metabolism[14] would seem to create
conditions favouring the maximisation of therapeutic
effect in the lung and minimisation of the risk of systemic
adverse effects.
Given that ciclesonide is being actively marketed as an
alternative to alternative to other inhaled corticosteroids,
our objective in this study was to systematically review
published randomised controlled trials of the effective-
ness and safety of ciclesonide compared to alternative
inhaled corticosteroids in people with asthma.
Methods
Search strategy
We performed literature searches on MEDLINE (from
1951), EMBASE, PUBMED and the COCHRANE LIBRARY
(The Cochrane Central Register of Controlled Trials)
using the following terms:
Ciclesonide, Alvesco, Budesonide, Pulmicort, Beclometh-
asone, Becotide, Becloforte, Fluticasone, Flixotide
We imported abstracts of citations from this search into an
electronic database. We also searched for "ciclesonide"
and "alvesco" on the web sites of the following internet
evidence sources:
• Drug and Therapeutics Bulletin http://www.dtb.org.uk/
dtb
￿ Succinct and Timely Evaluated Evidence Reviews
(STEER)
￿ Aggressive Research Intelligence Facility http://
www.bham.ac.uk/arif/index.html
￿ West Midlands Health Technology Assessment Collabo-
ration http://www.pcpoh.bham.ac.uk/publichealth/
wmhtac/
￿ International Network of Agencies for Health Technol-
ogy Assessment http://www.inahta.org
￿ Canadian Coordinating Office for Health Technology
Assessment http://www.ccohta.ca
Only the CCOHTA site yielded a result: a non-systematic
review. This was subsequently excluded.
Reference lists of retrieved articles were scrutinized for fur-
ther studies but yielded no additional papers.
Titles and abstracts were sifted by two reviewers and prior
to retrieval of full articles, the two reviewers independ-
ently assessed papers for inclusion. Cases of disagreementBMC Family Practice 2006, 7:34 http://www.biomedcentral.com/1471-2296/7/34
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were resolved by discussion (or, where necessary, delayed
until retrieval of the full text). All full text papers retrieved
were again assessed by the two independent reviewers for
inclusion and methodological quality (see Appendix 1).
There was no blinding to authors' names or institutions
and no scoring system (such as the Jadad score) was used.
Data were extracted by one reviewer.
Inclusion criteria for considering studies
Participants
Studies in human adults (i.e. people aged 18 and over)
with a diagnosis of chronic asthma were included. We did
not consider studies concerning acute asthma, chronic
obstructive pulmonary disease or allergic rhinitis.
Intervention
Studies concerning only inhalation of ciclesonide and
excluded those involving oral, nasal or intravenous
routes.
Comparators
Studies that compared ciclesonide to either budesonide or
beclomethasone or fluticasone and excluded studies com-
paring to placebo only or to other asthma treatments.
Outcome measures
we considered all reported outcomes although promi-
nence was given to patient based outcomes.
Study design
Prospective, randomized, controlled trials and or reviews
that were clearly systematic and carried out since the
beginning of 2004. Studies published only as abstracts
were included only if they contained sufficient methodo-
logical detail to enable critical appraisal. We considered
studies in all languages.
Results
Search results
Table 1 shows the results of the search. A total of five RCTs
were included (details in Table 2) [15-19]. No reviews or
abstracts qualified for inclusion. Two RCTs compared CIC
to BUD[15,19] and three RCTs compared CIC to FP [16-
18]. The Kanniess et al study[19] was the only RCT not
apparently sponsored by a pharmaceutical company man-
ufacturing CIC.
Quality of the evidence
All papers were critically appraised for methodological
quality based on the criteria shown in Table 3. All trials
involved small numbers (the largest number of partici-
pants completing the study being 19[18]) and were of
very short duration (maximum four weeks). Three of the
studies had drop-outs after randomization with attrition
rates varying from 5.25% – 30% [17-19]. In general, pop-
ulations were similar, although two studies did not
exclude smokers. Participants had mild asthma with
mean FEV1 greater than 90% of the predicted value in
three of the trials.
Three of the studies were cross-over trials and washout
periods were all of appropriate length [17-19]. Nave et al
and Richter et al were" within patient" trials, and therefore
similar to a crossover design, but both treatments were
given concurrently, presumably on the assumption that
oropharyngeal deposition was independent of treatment
but potentially confounded by short term changes in
oropharyngeal conditions. There were no parallel studies.
There was insufficient reporting to verify whether there
was good balance at baseline in the crossover trials. In the
Kanniess et al study there was also imbalance between the
population as a whole before receiving CIC and the same
population before receiving BUD.
Only one trial (Kanniess et al) was clearly double (or
more) blinded. Lee, Fardon et al and Lee, Haggart et al it
state that the inhalers were "masked" but it is not clear
whether their identity was withheld from the treatment
administrator or observer as well as the patient. None of
the trials reported whether, or how, they concealed alloca-
tion of treatment within participants or methods for ran-
domization. Overall there was no evidence of
performance bias.
Only two trials (Lee, Fardon et al and Lee, Haggert et al)
measured patient based outcomes as end points i.e. symp-
toms and QoL. All the others measured intermediate out-
comes and any interpretation of these results will require
an assessment of the degree to which these outcomes are
clinically significant.
Some studies (e.g. Kanniess et al [19]and to some extent
Lee, Fardon et al[17]) only reported pre and post treat-
ment results within the same treatment (i.e. CIC or the
comparator). Although the authors stated there was no
significant difference between treatments, they showed no
data or calculations.
Outcomes measured in the trials
Lung function tests
￿ FEV1, FVC, PEF etc.
Symptoms
￿ Symptom diary
￿ Use of rescue medication
Quality of LifeBMC Family Practice 2006, 7:34 http://www.biomedcentral.com/1471-2296/7/34
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￿ Mini Asthma quality of life (QoL) questionnaire[20]
Airway responsiveness to provoking agent
￿ This is measured in terms of the concentration of
inhaled provoking agent (adenosine monophosphate
(AMP) or metacholine) required to cause a 20% fall in
FEV1 (PC20). The initial dose is inhaled and the FEV1
measured subsequently. The dose is then doubled pro-
gressively until a 20% fall is recorded
Inflammatory markers
￿ Nitric oxide (NO) exhaled
￿ Inflammatory markers in the sputum
Hypothalamic-Pituitary-Adrenal (HPA) suppression (sys-
temic toxicity)
￿ Plasma cortisol response to human corticotrophin-
releasing factor (hCRF). This test has been shown to detect
Table 1: Search Results Summary
Search Medline Embase PubMed Cochrane Internet Total no. of 
papers 
without 
duplicates
Reviews Abstracts Papers after 
exclusion
(Ciclesonide 
or Alvesco) 
and 
(Budesonide 
or 
Pulmicort)
65 8 7716 6 4  ( 2  a r e  
duplicates 
with the FP 
search)
52
(Ciclesonide 
or Alvesco) 
and 
(Beclometh
asone or 
Becotide or 
Becloforte)
111002000
(Ciclesonide 
or Alvesco) 
and 
(Fluticasone 
or Flixotide)
45 6 4406 2 2  ( b o t h  a r e  
duplicates 
with the FP 
search)
33
Table 2: RCTs included in the review
Author Publisher Sponsor Study size Duration Comparator
Nave et al, 2005 European Journal of 
Clinical Pharmacology
ALTANA 18 Measurements at 0, 
15, 30, 45 and 60 mins
CIC 800 mcg (HFA 
MDI) od am Vs. BUD 
800 mcg (turbohaler) 
od am
Richter et al, 2005 Journal of Clinical 
Pharmacology
ALTANA 18 Measurements at 0, 
15, 30, 45 and 60 mins
CIC 800 mcg (HFA 
MDI) od am Vs. FP 
1000 mcg (HFA MDI) 
od am
Lee, Fardon et al, 2005 Chest AVENTIS 14 4 weeks Crossover 
with 2 week washout 
period
CIC 800 mcg (HFA 
MDI) bd Vs. FP 1000 
mcg (HFA MDI) bd
Lee, Haggart et al, 
2004
British Journal of 
Clinical Pharmacology
AVENTIS 19 4 weeks Crossover 
with 2 week washout 
period
CIC 400 mcg (HFA 
MDI) od am Vs. FP 
250 mcg (HFA MDI) 
bd
Kanniess et al, 2001 Pulmonary 
Pharmacology and 
Therapeutics
None declared 15 2 weeks (Cross over 
study with at least 3 
week washout period)
CIC 400 mcg (HFA 
MDI) od am Vs. BUD 
400 mcg (turbohaler) 
od amTable 3: RCT Methodological Characteristics
Author Year Population Comp. Duration Conceal-ment Blinding Random-isation Attrition Balance at baseline Equal handling
Kanniess et al 2001 No. completing 15 BUD 2 weeks crossover
3–8 weeks washout
No info about allocation Participant Yes Yes but no evidence of method 1 (5.25%) no yes
Mean age 33 Admin. no
Stable yes Observer yes
Non smokers 
only
yes Analyst ?
Mean FEV1 % 
pred:
94
Nave et al 2005 No. completing 18 BUD Combined treatment 
Oropharyngeal washings taken 
at 0 mins on day 1, 15 mins on 
day2, 30 mins on day 3, 45 mins 
on day 4 and 60 mins on day 5.
No info about allocation Participant no Yes but no evidence of method 0 yes yes
Mean age 33 Admin. no
Stable yes Observer no
Non smokers 
only
no Analyst ?
Mean FEV1 % 
pred:
?
Lee, Fardon 
et al
2005 No. completing 14 FP 4 weeks crossover 2 weeks 
washout
No info about allocation Participant yes Yes but no evidence of method 6 (30%) yes yes
Mean age 47 Admin. ?
Stable yes Observer ?
Non smokers 
only
yes Analyst ?
Mean FEV1 % 
pred:
77
Lee, Haggart 
et al
2004 No. completing 19 FP 4 weeks crossover 2 weeks 
washout
No info about allocation Participant yes Yes but no evidence of method 4 (17.5%) yes yes
Mean age 45 Admin. ?
Stable yes Observer ?
Non smokers 
only
yes Analyst ?
Mean FEV1 % 
pred:
90
Richter et al 2005 No. completing 18 FP Combined treatment 
Treatement 5–14 days (5 
treatments in total at 0, 15, 30, 
45 and 60 minutes). Minimum 1 
day washout
No info about allocation Participant no Yes but no evidence of method 0 yes yes
Mean age 37 Admin. no
Stable yes Observer no
Non smokers 
only
no Analyst ?
Mean FEV1 % 
pred:
91BMC Family Practice 2006, 7:34 http://www.biomedcentral.com/1471-2296/7/34
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impaired adrenal reserves in corticosteroid-treated
patients[21].
￿ Urine cortisol
Oropharyngeal deposition
￿ This is the amount of inhaled steroid that does not enter
the lung and is deposited in the oropharynx.
Table 4 shows the comparative results from the trials.
Results from the trials
None of the trials showed CIC to have any benefit over
either FP or BUD for the outcomes of lung function,
symptoms, quality of life, airway responsiveness to a pro-
voking agent or inflammatory markers.
Lee, Fardon et al studied HPA suppression. At the end of
each four week treatment period, of either CIC 800 mcg
bd or FP 1000 mcg bd, a 10 hour overnight urine collec-
tion (OUC) was taken and plasma cortisol response to a
100 mcg bolus of hCRF was assessed at 30 and 60 min-
utes. The authors state that data were logarithmically
transformed to normalize the distribution but give no
comment on how the data were skewed. Results compar-
ing CIC and FP are reported as the geometric mean fold
difference (GMFD) but there is no explanation as to how
these values were calculated. By definition a GMFD of 1.0
means no difference.
When comparing the two treatments there was no signifi-
cant difference in outcome with respect to plasma cortisol
response to hCRF. However, there was significantly more
suppression of urinary cortisol after FP than CIC (but with
95% CI of 1.1–2.0 this was only barely so). The results for
plasma cortisol levels 60 minutes after hCRF are not
reported in the table but the authors state that there was
no significant difference between pretreatment and post
treatment FP levels.
Two trials studied orpharyngeal deposition and were very
similar in nature[15,16]. Nave et al compared CIC 800
mcg via a hydrofluoroalkane-pressurised metered-dose
inhaler (HFA MDI) to BUD 800 mcg via a chlorofluoro-
carbon-pressurised metered dose inhaler (CFC MDI).
Richter et al compared CIC 800 mcg to FP 1000 mcg each
via HFA MDI. Curves were plotted for recovery of each
drug in rinsing solution against time after administration
and then the molar area under the curve for 0 – 60 min-
utes (AUC0–60 min) was calculated for CIC, des-CIC and
BUD (or FP) to allow direct comparisons.
The Nave et al study shows that the combined deposition
of CIC and des-CIC in the oropharynx was less than half
(47%) of that of BUD. Only 8% of the CIC deposited was
converted into the active metabolite des-CIC (suggesting
a lack of converting esterases in the oropharynx). Overall
the concentration of des-CIC in the oropharynx 60 min-
utes after inhalation was only 4% of the BUD concentra-
tion (i.e. 25 times more BUD than des-CIC).
The Richter et al study shows that the combined deposi-
tion of CIC and des-CIC in the oropharynx was only 53%
of that of FP. Furthermore only 17% of the CIC deposited
was converted into the active metabolite des-CIC. The
concentration of des-CIC in the oropharynx 60 minutes
after inhalation was only 8% of the FP concentration (i.e.
12.5 times more FP than des-CIC).
Discussion
There are few data directly comparing CIC to other ICS
and no published evidence directly comparing CIC to
BDP specifically. None of the RCTs showed CIC to offer
any benefit over BUD or FP for effectiveness i.e. none of
the RCTs showed CIC to offer any benefit over BUD or FP
for any patient based outcomes (asthma symptoms or
QoL in these trials). Furthermore none of the trials dem-
onstrated any benefit from CIC over BUD or FP for indi-
rect outcomes of efficacy i.e. lung function, improving
response to AMP or metacholine as provoking agents or
for decreasing markers of inflammation.
All but one of the trials were sponsored by drug compa-
nies manufacturing CIC and seem to endeavour to dem-
onstrate CIC to have equivalent efficacy to other ICS but
with an improved safety profile. However, none of the
studies report analyses which exclude superiority of one
treatment over another (hence it is not possible to con-
clude that CIC was equivalent to FP or BUD for any effi-
cacy outcomes) and the evidence regarding safety is not
conclusive.
The conflicting evidence from the Lee, Fardon et al trial
might indicate that CIC has less systemic adverse effects
than FP. Challenges to this conclusion, however, are two-
fold. The first comes from the trial itself. This is the only
published trial comparing HPA suppression between CIC
and other ICS and the results were not unequivocal. There
were also some methodological weaknesses in the trial.
There was no evidence of concealment of allocation, an
attrition rate of 30%, no evidence of blinding other than
the participants and the choice of a comparator (i.e. FP)
that is reported to have the highest risk of side effects[10]
(there is no published evidence directly comparing HPA
suppression after treatment with CIC to either BUD or
BDP).
The second challenge relates to the correlation between
the intermediate outcome of HPA suppression measuredTable 4: Summary of Results from RCTs Comparing Ciclesonide to Budesonide or Fluticasone
Trial Results CIC vs. comparator
Lung Function
Lee, Fardon et al Authors report no significant difference (CIC vs. FP)
Lee, Haggart et al 95% CI for CIC vs. FP
FEV1 (l) -0.15, 0.06
Kanniess et al Authors report no significant difference (CIC vs. BUD)
Patient Symptoms
Lee, Fardon et al Authors report no significant difference (CIC vs. FP)
Lee, Haggart et al
95% CI for CIC vs. FP
PEF (am) (l/min) -12, 14
PEF (pm) (l/min) -11. 17
Asthma symptom score (am) -0.3, 0.1
Asthma symptom score (pm) -0.3, 0.1
Rescue (am) (puffs/day) -0.4, 0.2
Rescue (am) (puffs/day) -0.3, 0.1
Quality of Life
Lee, Fardon et al Authors report no significant difference (CIC vs. FP)
Lee, Haggart et al
95% CI for CIC vs. FP
Activities -0.26, 0.92
Symptoms -0.45, 0.56
Emotions -0.76, 0.37
Environment -1.08, 0.02
Overall -0.43, 0.37
Airway Responsiveness to Provoking Agent
Lee, Fardon et al
CIC vs. FP
GMFD 95% CI P
PC20 FEV1 (metacholine) 0.1 -0.7-0.5 >0.05
Lee, Haggart et al
95% CI for CIC vs. FP
PC20 FEV1 (metacholine) -1.2, 0.4
Kanniess et al Authors report no significant difference (CIC vs. BUD)
Inflammatory Markers
Lee, Fardon et al
CIC vs. FP
GMFD 95% CI P
Exhaled Nitric oxide 1.4 0.8–2.5 >0.05
Lee, Haggart et al
95% CI for CIC vs. FPat four weeks after the start of treatment with ICS correlates and clinically adverse effects
for patients. HPA suppression is a well reported outcome of both short and long term ICS
use [22-25]. However the clinical significance of such suppression is uncertain[6,22,25].
Current evidence suggests that ICS do not cause important systemic side effects in doses
of up to 400 mcg/day in children and 800 mcg/day in adults,[26] and even in doses of
more than 1 mg/day there is no conclusive evidence that patients are at any increased risk
from side-effects[25,23]. Hanania et al report HPA suppression and decreased bone den-
sity after regular use of conventional doses of ICS for asthma[24] but there is no conclu-
sive evidence of a clinically adverse effect e.g. bone fractures.
Further long term studies are required to determine the long term risk of clinically signif-
icant adverse effects as a result of HPA suppression associated with ICS use in general and
specifically with CIC. In the meantime it is not possible to conclude that CIC offers any
benefit over other ICS in terms of systemic adverse effects.
With respect to local adverse effects there are similar challenges. Although, CIC might be
expected to have fewer local adverse effects (due to the inhaled agent being its inactive
metabolite des-CIC) there is no logical explanation why CIC should be deposited in the
oropharynx in such smaller amounts than FP or BUD. In the Nave et al study the aut
point out that the difference in deposition could be due to the different inhaler dev
used. HFA MDIs have been shown to produce ICS with a smaller particle size than 
MDIs[27] resulting in 17% of a 200 mcg dose of BUD being respirable[15] compare
48% of a 200 mcg dose of CIC[8,13]. However, in the Richer et al study both inhalers 
HFA MDI and the authors make no mention of why deposition might be less given
both treatments are inhaled via the same device. Neither trial was blinded in any 
which could have been a source of bias, and the lack of a logical explanation for 
vastly different deposition rates makes it difficult to draw any definite conclusion. Fu
studies (preferably parallel) with larger populations are required before conclu
whether CIC offers any benefit in terms of local adverse effects
In addition to the RCTs outlined above there are number of abstracts that have no
been published as full papers. These trials involved substantially larger numbers of
ticipants and ran for longer duration but have not been included in the analysis since
contained insufficient detail for critical appraisal of methodological quality. The re
reported in these abstracts do not alter the conclusions drawn from the full papers bu
reported for interest in Appendix 1.
Exhaled Nitric oxide -2.1, 7.3
Kanniess et al Authors report no significant difference (CIC vs. BUD)
HPA Suppression
Lee, Fardon et al
CIC vs. FP
GMFD 95% CI P
Cortisol pre-hCRF 1.1 0.9–1.2 >0.05
Cortisol 30 mins post-hCRF 1.0 0.9–1.2 >0.05
OUC 1.5 1.1–2.0 <0.05
Oropharyngeal Deposition
Nave et al Test Reference Point Estimates 
of Molar 
Adjusted 
AUC0–60 min 
Ratios
95% CI P value
des-CIC BUD 0.04 0.02 – 0.05 < 0.0001
des-CIC CI C 0.08 0.06 – 0.11 < 0.0001
des-CIC + CIC BUD 0.47 0.38 – 0.59 < 0.0001
Richter et al
Test Reference Point Estimates 
of Molar 
Adjusted 
AUC0–60 min 
Ratios
95% CI P value
des-CIC FP 0.08 0.05 – 0.11 <0.00001
des-CIC CIC 0.17 0.13 – 0.22 <0.00001
des-CIC + CIC FP 0.53 0.40 – 0.69 <0.001
Table 4: Summary of Results from RCTs Comparing Ciclesonide to Budesonide or Fluticasone (Continued)BMC Family Practice 2006, 7:34 http://www.biomedcentral.com/1471-2296/7/34
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Irrespective of any clinical benefit or not CIC is more
expensive compared to BEC, BUD and FP as shown in
Table 5. Treatment with CIC would come at substantial
financial cost since at high dose (1000 mcg daily) CIC is
5.13 as expensive as BDP, 2.27 times as expensive as BUD
(800 mcg daily) and 1.39 times as expensive as FP.
Any advantage that CIC might have over existing, cheaper,
ICS is predicated on assertions regarding the long term
dangers of ICS use. "Steroid phobia" is recognised in other
fields[28] and is likely to form the basis for effective direct
to patient marketing of CIC, where such advertising is per-
mitted. However, the evidence base on long term inhaled
steroid use is far from certain and it is not clear whether
the dangers are such that the precautionary principle is
justified.
Although it is clear that the evidence base for ciclesonide
will expand considerably with the publication of the
larger studies excluded from this review, we believe it is
important to highlight the limited nature of the evidence
base that is currently available for scrutiny by clinicians
and policy makers seeking to practice and support evi-
dence based medicine.
Conclusion
There is very little evidence that has been published in full
comparing CIC to other ICS. Current evidence is restricted
to very small, phase II studies of low power. These dem-
onstrate CIC has similar effectiveness and efficacy to FP
and BUD (though equivalence is not certain) and findings
regarding oral deposition and HPA suppression are incon-
clusive. There is no direct comparative evidence that CIC
causes fewer side effects since none of the studies reported
patient-based outcomes. Treatment with CIC would also
come at substantial financial cost compared to other ICS.
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Appendix 1
The search resulted in the retrieval of eight abstracts
recorded in Table 6. The Hansel et al and Engelstatter et al
abstracts had the same author group, trial characterists
and results and were assumed to be from the same trial.
Hence only one (Hansel et al) was included. The Fardon
et al abstract appeared to be an abstract form of the Lee,
Haggart  et al full paper and hence the abstract was
excluded. The Derom et al and Pauwels et al abstracts were
identical in all ways other than that the former had 25 par-
ticipants and the latter 26. This could have been a typo-
Table 5: Cost of Inhaled Corticosteroids at various doses
ICS Inhaler Ex-valve Daily dose (mcg) Cost for 28 days treatment 
(€)
Beclomethasone MDI 100 1.29
Beclomethasone MDI 400 2.28
Beclomethasone MDI 1000 9.16
Budesonide Turbohaler 100 2.05
Budesonide Turbohaler 400 10.36
Budesonide Turbohaler 800 20.72
Fluticasone HFA MDI 100 2.53
Fluticasone HFA MDI 500 19.84
Fluticasone HFA MDI 1000 33.73
Ciclesonide HFA MDI 100 6.66
Ciclesonide HFA MDI 400 15.68
Ciclesonide HFA MDI 1000 47.04
Source: Department of Health Drug Tariff May 2005BMC Family Practice 2006, 7:34 http://www.biomedcentral.com/1471-2296/7/34
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graphical error and they were assumed to be abstracts of
the same trial and only the Derom et al abstract included.
The Biberger et al and Ukena et al abstracts had exactly the
same author group, the same number of trial participants,
the same trial and comparator doses but a slight difference
in the results i.e. FEV1 increase after CIC and FP was 411
ml and 319 ml respectively in Biberger et al and 416 ml
and 321 ml respectively in Ukena et al with all other
results the same. It was assumed that the data had been
analysed differently in each case but that these results rep-
resented the same trial and only one (Ukena et al) was
included. Table 7 shows details of the abstracts.
Abstracts measuring lung function as end point
￿ Ukena et al reported significantly greater improvement
in both FEV1 and FVC after CIC compared to BUD (P <
0.0001 and P = 0.0185 respectively).
￿ Hansel et al did not demonstrate any significant differ-
ence between CIC over BUD.
￿ Boulet et al reported superiority of CIC over FP for FVC
(p < 0.01) but an insignificant difference for FEV1.
Abstracts measuring patient symptoms as end point
￿ Ukena et al reported no significant difference in asthma
symptom improvement between CIC and BUD, although
CIC did demonstrate earlier onset of treatment effect
(three days versus two weeks).
￿ Hansel et al did not demonstrate any significant differ-
ence between CIC over BUD
￿ Boulet et al reported no significant difference in asthma
symptom changes between CIC and FP although the per-
centage of symptom free days was significantly higher in
CIC vs. FP (43% vs. 43%, p = 0.0288)
Abstracts measuring airway responsiveness to provoking 
agent as end point
￿ Derom et al reported no significant difference between
CIC and FP for PC20 (AMP) FEV1
Abstracts measuring HPA suppression as end point
￿ Ukena et al report no significant changes from baseline
for urine cortisol levels for either CIC or BUD but do not
compare the two treatments.
￿ Hansel et al report no significant changes from baseline
for urine cortisol levels after CIC but a significant decrease
after BUD. However they do not compare the two treat-
ments.
￿ Derom et al report no significant changes from baseline
for urine cortisol levels after CIC but a significant decrease
after FP. However they do not compare the two treat-
ments.
Summary
None of the results reported in the abstracts challenge the
conclusions of the review.
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